TREATMENT OF OBESITY AND INSULIN RESISTANCE IN THE NON-HUMAN PRIMATE

非人类灵长类动物肥胖和胰岛素抵抗的治疗

• 批准号: 8357811
• 负责人: KEVIN L GROVE
• 金额: $ 3.63万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357811
• 关键词: Agonist; Body Weight; Body mass index; Cardiovascular Physiology; Chronic; Coronary heart disease; Diabetes Mellitus; Diet; Dose; Eating; Energy Intake; Energy Metabolism; Expenditure; Funding; Grant; Health; Healthcare; Human; Insulin Resistance; Macaca mulatta; Monkeys; National Center for Research Resources; Obesity; Peripheral; Persons; Phase; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Risk; Source; United States National Institutes of Health; Woman; blood glucose regulation; cost; economic cost; heart disease risk; improved; insight; men; nonhuman primate; obesity treatment; phase 1 study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Obesity is one of the major health risk facing the developed world, significantly increasing the risk of coronary disease, and of diabetes. It has recently been shown that for every "point" by which a person's body mass index (BMI) exceeds 25, there is an associated increase (5% in men and 7% in women) in the risk of cardiac disease. Beyond the terrible human costs there are significant economic costs associated with health care for such an obese population. An estimated 9.4% of US healthcare expenditure is directly related to "obesity and inactivity", while recent costs due to diabetes were estimated at $98 billion per annum. There are two main aims of this study: Phase 1 will determine the efficacy of peripheral melanocortin agonist treatment on food intake in rhesus macaques. These are exploratory studies to optimize dose given s.c. Phase 2 will determine if chronic eripheral melanocortin agonist treatment can reduce body weight and adiposity in diet-induced obese (DIO) monkeys. This study will also determine if changes in body weight are do to chronic changes in caloric intake and/or increased energy expenditure. Finally, these studies will determine if this chronic melanocortin treatment improves glucose homeostasis and cardiovascular function. These are extensive studies that will generate critical insight into the potential of melanocortin agonist as a therapy for human obesity and diabetes.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 肥胖是发达国家面临的主要健康风险之一，显著增加了冠心病和糖尿病的风险。最近的研究表明，一个人的身体质量指数（BMI）每超过25个“点”，心脏病的风险就会相应增加（男性5%，女性7%）。除了可怕的人力成本之外，还有与如此肥胖人口的医疗保健相关的重大经济成本。据估计，美国医疗保健支出的9.4%与“肥胖和不活动”直接相关，而最近由于糖尿病造成的费用估计为每年980亿美元。本研究有两个主要目的：第1阶段将确定外周黑皮质素激动剂治疗对恒河猴摄食量的疗效。这些是探索性研究，旨在优化s.c.给药剂量。第2阶段将确定长期外周黑皮质素激动剂治疗是否可以减轻饮食诱导的肥胖（DIO）猴的体重和肥胖。 本研究还将确定体重变化是否与热量摄入和/或能量消耗增加的慢性变化有关。 最后，这些研究将确定这种长期黑皮质素治疗是否能改善葡萄糖稳态和心血管功能。 这些是广泛的研究，将产生关键的洞察黑皮质素激动剂作为一种治疗人类肥胖和糖尿病的潜力。